Information Provided By: 
Fly News Breaks for April 3, 2018
EXAS
Apr 3, 2018 | 06:42 EDT
BTIG analyst Sean Lavin upgraded Exact Sciences to Buy with a $60 price target. Since November, the stock has fallen 35%, which provides an "attractive entry point," Lavin tells investors in a research note. He expects the shares to rally from here as Cologuard adoption grows "towards standard of care." The analyst says he's always felt Cologuard should replace most colonoscopies over time and should increase the number of people screening.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
